|
KMID : 0363319910120020001
|
|
Journal of Korean Oriental Internal Medicine
1991 Volume.12 No. 2 p.1 ~ p.15
|
|
|
Antitumor Effects of Bigihwan on Tumor Cells derived from Leukemia and Lymphoma Patients
|
|
Han Sang-Il
Kang Byung-Ki
|
|
|
Abstract
|
|
|
Bigihwan which has been widely used in Oh-jug in oriental Medicine was investigated on its antitumor effect employing blood cancer cell lines. K 562 derived from human erytholeukemia, Raji from lymphoma and MO₄ from hlastogenic cancer were used in this study to see the analytical evaluation of Bigihwan’ s antitumor effect using three different kinds of methods such as ³H-thymidine up take assay. MTT assay and live cell counts by Trypan blue assay.
The result obtained are as follows.
1. When higher than 10% Bigihwan was treated. inhibitory effect of tumor killing action was observed showing the increasing order of MO₄, K 562 and Raji(Fig. 3).
2. When 1 to 5% of Bigi-hwan was treated, 4 to 30% of tumor cell survival was observed according to various blood tumor cell lines suggesting that antitumor effect of Bigi-hwan was different as the characteristics of tumor cells showing 70 to 95% cell killing effent(Fig. 4).
3. Compared the survivals of cells by relative scales though the initial cpm was variable because of different cell growth rate. Raji was most effective being killed 95% by the treatment of 1% Bigihwan while Raji and K562 showed 93% by 5% Bigihwan.(Fig. 5)
4. The survival rate of Raji derived from Burkitt lymphoma was rather increased to 2.3 times when Bigihwan concentration was increased from 1 to 10% lmplying of refraining from over use of this anticancer drug. specially to lymphoma patients(Fig. 5).
5. Bigihwan was most effective to K 562 and then MO₄ showing 95% tumor cell death by using 1% of this anticancer drug while it was least effective to Raji showing only 68% of tumor cell death(Fig.7).
6. Judging from the all the analytical methods used in this study, through all different three tumor cell lines. Bigihwan was most effective to K 562 derived from human erythroleukemia.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|